GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harrow Inc (NAS:HROW) » Definitions » Cyclically Adjusted PB Ratio

Harrow (Harrow) Cyclically Adjusted PB Ratio : 20.83 (As of May. 24, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Harrow Cyclically Adjusted PB Ratio?

As of today (2024-05-24), Harrow's current share price is $17.50. Harrow's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $0.84. Harrow's Cyclically Adjusted PB Ratio for today is 20.83.

The historical rank and industry rank for Harrow's Cyclically Adjusted PB Ratio or its related term are showing as below:

HROW' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.72   Med: 12.58   Max: 65
Current: 20.46

During the past years, Harrow's highest Cyclically Adjusted PB Ratio was 65.00. The lowest was 0.72. And the median was 12.58.

HROW's Cyclically Adjusted PB Ratio is ranked worse than
97.67% of 687 companies
in the Drug Manufacturers industry
Industry Median: 1.88 vs HROW: 20.46

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Harrow's adjusted book value per share data for the three months ended in Mar. 2024 was $1.712. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.84 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Harrow Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Harrow's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harrow Cyclically Adjusted PB Ratio Chart

Harrow Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 69.07 19.34 9.21 16.24 13.43

Harrow Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.17 22.65 17.07 13.43 15.72

Competitive Comparison of Harrow's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Harrow's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harrow's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Harrow's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Harrow's Cyclically Adjusted PB Ratio falls into.



Harrow Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Harrow's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=17.50/0.84
=20.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harrow's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Harrow's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.712/131.7762*131.7762
=1.712

Current CPI (Mar. 2024) = 131.7762.

Harrow Quarterly Data

Book Value per Share CPI Adj_Book
201406 1.319 100.560 1.728
201409 1.112 100.428 1.459
201412 0.880 99.070 1.171
201503 0.663 99.621 0.877
201506 0.549 100.684 0.719
201509 0.232 100.392 0.305
201512 -0.142 99.792 -0.188
201603 0.670 100.470 0.879
201606 0.425 101.688 0.551
201609 0.214 101.861 0.277
201612 0.345 101.863 0.446
201703 0.266 102.862 0.341
201706 0.381 103.349 0.486
201709 0.186 104.136 0.235
201712 0.127 104.011 0.161
201803 0.004 105.290 0.005
201806 0.177 106.317 0.219
201809 0.197 106.507 0.244
201812 1.017 105.998 1.264
201903 1.499 107.251 1.842
201906 1.395 108.070 1.701
201909 0.952 108.329 1.158
201912 1.086 108.420 1.320
202003 0.599 108.902 0.725
202006 0.613 108.767 0.743
202009 0.985 109.815 1.182
202012 1.056 109.897 1.266
202103 1.086 111.754 1.281
202106 0.863 114.631 0.992
202109 0.617 115.734 0.703
202112 0.420 117.630 0.471
202203 0.373 121.301 0.405
202206 0.212 125.017 0.223
202209 0.045 125.227 0.047
202212 0.923 125.222 0.971
202303 0.728 127.348 0.753
202306 0.740 128.729 0.758
202309 2.157 129.860 2.189
202312 2.012 129.419 2.049
202403 1.712 131.776 1.712

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Harrow  (NAS:HROW) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Harrow Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Harrow's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Harrow (Harrow) Business Description

Industry
Traded in Other Exchanges
N/A
Address
102 Woodmont Boulevard, Suite 610, Nashville, TN, USA, 37205
Harrow Inc is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market. Harrow helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans each year.
Executives
Mark L Baum director, 10 percent owner, officer: Chief Executive Officer C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Martin A. Makary director 102 WOODMONT BLVD., SUITE 610, NASHVILLE TN 37205
Van Horn R. Lawrence director 354 COOL SPRINGS BLVD., SUITE 106, FRANKLIN TN 37067
Andrew Boll officer: VP, Accounting and Reporting 437 S HWY 101, STE 209, SOLANA BEACH CA 92075
Lindstrom Richard L Md director 2811 WESTWOOD PL, WAYZATA MN 55391
Perry J. Sternberg director 102 WOODMONT BLVD., SUITE 610, NASHVILLE TN 37205
Teresa Sparks director 40 BURTON HILLS BOULEVARD SUITE 500, NASHVILLE TN 37215
Robert J Kammer director, 10 percent owner, officer: Chairman of the Board 1440 28TH STREET, SUITE 9, BOULDER CO 80303
Longboard Capital Advisors, Llc other: Institutional Investor 9665 WILSHIRE BLVD., SUITE 430, BEVERLY HILLS CA 90212
Brett Conrad other: Managing Mbr of Longboard Cap. 1312 CEDAR ST., SANTA MONICA CA 90405
Clayton D Edwards officer: Chief Operating Officer 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Anthony Principi director 2300 WEST PLANO PARKWAY, M/S D2420, PLANO TX 75244
Donald Paul Miloni 10 percent owner 1425 GREENWOOD LANE, GREENWOOD VILLAGE CO 80125
John P. Saharek officer: Chief Commercial Officer 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130